Compare Dollar General Corp. (DG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs TG Therapeutics Inc — how do they compare? Dollar General Corp. trades at $127.23 (market cap $27.42B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Dollar General Corp. is far larger — about 3.4× TG Therapeutics Inc's market cap, and Dollar General Corp. pays a 1.9% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and TG Therapeutics Inc for 16 Days on average.
| DG | TGTX | |
|---|---|---|
Market Cap | $27.42B | $8.16B |
Volume | 2,291,517 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $59.06 |
52-Week Low | $95.94 | $26.94 |
Typical Hold Time | 59 Days | 16 Days |
Enterprise Value | $41.60B | $8.37B |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $124.27, up 1.73% today, with a bullish technical signal from moving averages and strong analyst support (55.77% buy ratings). Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.48 exceeding the $2.01 estimate. The company benefits from tariff refunds boosting margins and is expanding delivery via Instacart and scaling its DG Media Network for growth.
The outlook is positive, with a consensus price target of $137.27 implying ~10% upside. Key opportunities include margin recovery initiatives and value-focused merchandising, but risks persist from consumer pressure and competitive discount retail dynamics. Net cash flow improved to $395 million in 2025, though profit margins have narrowed from 7.01% in 2022 to 2.77% in 2025.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
